In 2023, the unparalleled generosity of our donors set the stage for a transformative year at the Leukemia and Lymphoma Society of Canada. You have directly fueled the advancement of medical research, while also significantly enhancing quality of life for those affected by blood cancers. Your support ignited the expansion of innovative research projects aimed at reshaping the future of cancer care. Your contributions were the lifeblood of much needed programs and targeted initiatives, crafted to address the unique challenges faced by our community. Your contributions are creating a legacy of innovation, compassion and care making you true architects of change.
88.4% Fundraising revenue

6% Bequests

5.6% Investment & other income

Your Generosity in Action
Information reflects fiscal year ending on June 30, 2023.

**EXPENDITURES**

- **62%**
  - Service delivery to the community
    - **30%** Research
    - **18%** Patient support
    - **14%** Public education

- **23%**
  - Rallying supporters through fundraising events

- **15%**
  - Strengthening operations to match community needs
4,000 phone calls and emails responded to

309 individuals engaged in our virtual support groups

52 virtual support meetings held

773 people financially supported for medical travel in our One Kilometre at a Time subsidy program

438 requests for individuals seeking peer matches in our First Connection program
7,319 people engaged in educational events
25 educational animated videos created
1,700 registrants for a single webcast (Causes of blood cancer)
Through your invaluable support, healthcare providers have increased their understanding of the rapidly evolving blood cancer landscape. Leveraging our comprehensive continuing education programs and resources, they have enhanced their capabilities to offer superior care and support to individuals impacted by blood cancer. This advancement underscores the pivotal role of our collaborative efforts in fostering a well-informed healthcare community, equipped to confront the challenges posed by blood cancers with greater expertise and empathy.
1st pediatric oncology day hosted by the LLSC at the 2023 Canadian Association of Nurses in Oncology Conference

1,000 healthcare professionals trained through our continuing education platform

132 healthcare professionals in 10 provinces registered for our After Cancer Care continuing education training
Your generous support has been instrumental in advancing our goal of transforming the research landscape by prioritizing collaboration over competition. Thanks to you the scope of inquiry and innovation has not only expanded with enhanced capacity to tackle complex challenges but also fostered a spirit of unity and shared purpose within the research community. Your contributions have paved the way for groundbreaking discoveries, exploration of new research frontiers and remarkable progress.
$5,009,300 invested in the work of 37 blood cancer researchers across Canada including:

- $2,097,940 Operating Grants
- $773,040 Translation Research
- $718,108 Pediatric Blood Cancer Research
- $689,120 Quality of Life Research
Your unparalleled generosity over the past year has been nothing short of transformative, elevating hope and pioneering the advancement of research and our tailored support services for those bravely facing blood cancers. Your contributions are the cornerstone of life-saving research breakthroughs and innovation. We stand in awe of your commitment to making a profound difference, and it is with heartfelt gratitude that we acknowledge the vital role you play in the journey towards curing blood cancers. Your support not only lights the path to recovery for many but also marks you as true champions and blood cancer heroes.
This distinguished collective of our nation's business and community leaders has transcended traditional philanthropy, each raising over $50,000 in the groundbreaking Visionaries of the Year competition—a forward-thinking evolution of the esteemed Man and Woman of the Year contest.

Over an intensive ten-week campaign, these trailblazers have channeled their unparalleled skills, zeal, and competitive drive into the race for blood cancer cures. Their achievements have not only secured them the prestigious title of Research Champions but have also heralded a new epoch in philanthropy—one marked by a spirited rivalry for the betterment of humanity and the upliftment of our communities.

We extend our profound gratitude to this extraordinary group of visionaries. Your remarkable contributions and indomitable spirit have set a new benchmark for leadership and generosity, inspiring a wave of positive change that resonates far beyond our immediate horizon. Thank you for your monumental efforts in propelling us forward, illuminating the path with your drive, enthusiasm, and unwavering commitment.
$136,704
Jaime Moar
Owner, The Well Studio

$180,609
Geoff Tessarolo
CFO, VanMar Constructors Inc

$341,604
Dean Iwai
CEO, KTI Limited

$50,288
Nicol Kalman
Founder, AIP Connect

$53,357
Mark Stevens
Vice President, B.D. Stevens LTD

$55,070
Greg Smith
Program Director, VOCM

$58,215
Kevin Parton
Partner and Senior Advisor, VELA Wealth

$101,177
Paul MacMillan
Technical Editor/Writer, L3Harris

$60,826
Sabrina Silvano
Lawyer, Pringle & Associés Avocats

$60,867
Michael Baratta
Partner, KPMG LLP

$116,585
Joey Baldacchino
Construction Director, Groupe Melatti

$51,118
Owen Payne
General Counsel, Imperial Capital Limited

$180,609
Geoff Tessarolo
CFO, VanMar Constructors Inc

$116,585
Joey Baldacchino
Construction Director, Groupe Melatti

$136,704
Jaime Moar
Owner, The Well Studio

$341,604
Dean Iwai
CEO, KTI Limited

$50,288
Nicol Kalman
Founder, AIP Connect

$53,357
Mark Stevens
Vice President, B.D. Stevens LTD

$55,070
Greg Smith
Program Director, VOCM

$101,177
Paul MacMillan
Technical Editor/Writer, L3Harris

$60,826
Sabrina Silvano
Lawyer, Pringle & Associés Avocats

$60,867
Michael Baratta
Partner, KPMG LLP

$116,585
Joey Baldacchino
Construction Director, Groupe Melatti

$51,118
Owen Payne
General Counsel, Imperial Capital Limited

$180,609
Geoff Tessarolo
CFO, VanMar Constructors Inc

$58,215
Kevin Parton
Partner and Senior Advisor, VELA Wealth
We extend our deepest gratitude to the extraordinary teams and individuals whose unwavering dedication and tireless efforts have propelled us closer to finding cures for blood cancers. Your remarkable achievements in Light The Night have set a new standard of excellence, showcasing the power of collective action and the impact of compassionate giving. Your contributions have not only fueled groundbreaking research but also offered hope and support to countless individuals facing these challenging conditions. As we reflect on this past year’s successes, we are inspired by your passion and commitment. It is with profound appreciation that we celebrate your monumental achievements, and hope that you will continue this journey with us, motivated by the knowledge that together, we are making a significant difference in the lives of those affected by blood cancers.
<table>
<thead>
<tr>
<th>Location</th>
<th>Total Amount</th>
<th>Company/Individual</th>
</tr>
</thead>
<tbody>
<tr>
<td>Halifax</td>
<td>$186,806</td>
<td>Porsche of Halifax</td>
</tr>
<tr>
<td></td>
<td>$15,652</td>
<td>Lucas Arsenault</td>
</tr>
<tr>
<td>Montreal</td>
<td>$109,408</td>
<td>Laurentien Electrique</td>
</tr>
<tr>
<td></td>
<td>$32,009</td>
<td>Cristina Carlone</td>
</tr>
<tr>
<td>Ottawa</td>
<td>$33,134</td>
<td>Pomerleau</td>
</tr>
<tr>
<td></td>
<td>$25,307</td>
<td>Jean-Claude Coelho</td>
</tr>
<tr>
<td>Toronto</td>
<td>$271,278</td>
<td>Marsh Canada (The Jim Abernethy Challenge)</td>
</tr>
<tr>
<td></td>
<td>$16,526</td>
<td>Joanne Archibald</td>
</tr>
<tr>
<td>Calgary</td>
<td>$42,098</td>
<td>Real Canadian Superstore/Extra Foods Calgary Area Districts</td>
</tr>
<tr>
<td></td>
<td>$13,395</td>
<td>Mike Mestinsek, K.C</td>
</tr>
<tr>
<td>Vancouver</td>
<td>$117,437</td>
<td>UFCW BC Team</td>
</tr>
<tr>
<td></td>
<td>$104,136</td>
<td>The Spotzl Family (#RachelStrong)</td>
</tr>
</tbody>
</table>
Thanks to the invaluable support of our donors, individuals grappling with blood cancers are not alone. Be it acute myeloid leukemia, Waldenström macroglobulinemia, or any of the 137 blood cancer subtypes, your generosity facilitates access to a wide array of services, each carefully tailored to meet the unique needs of those affected by blood cancer. From enabling participation in clinical trials offering the latest treatments to providing emotional support and educational resources, every person touched by blood cancer knows they have a supportive community behind them every step of the way. Personalized support is available toll-free at 1-833-222-4884 or through a Community Services Lead. For more information, please visit our one-on-one personalized support page.
In 2023 LLSC introduced our participation in the Dare to Dream Project, a global initiative unlike any other. It is a daring initiative to change the paradigm of cancer research, treatment and care for children, through research, education and advocacy.

DARE to Dream of a day when children survive cancer — and thrive in spite of it.

TRANSFORM PEDIATRIC RESEARCH

We are investing more in pediatric research than ever before, including: funding more research through our Pediatric Blood Cancer Research Innovation Grant and contributing to a groundbreaking Pediatric Acute Leukemia Master Clinical Trial (PedAL) that will see Canada among the list of participating countries that will benefit from the trial.

ADVANCE POLICY & ADVOCACY

For a child diagnosed with cancer, access to lifesaving treatment cannot wait. Advocacy efforts drive critical access to the latest in innovative care, and makes those treatments available closer to home.

EXPAND PEDIATRIC SUPPORT & SERVICES

Families caring for a child with cancer have unique and immediate needs. Continued access to personalized support helps families manage, cope and take control of their cancer experience.

Kids are different. And it’s why children with cancer should be treated with drugs tailored to their unique biology and disease. Cancers in kids are biologically different from adult cancers, and the way young bodies respond to and recover from treatment is unique as well.

Many children who survive blood cancer develop secondary cancers, severe physical and cognitive impairments, cardiac problems, and a range of ailments the medical community is only beginning to understand. In addition to the extreme physical challenges, the emotional and financial toll of cancer for patients and their families is significant.
Do you or your loved one need support?
Don’t hesitate to contact us, we’re here to help.
1 833 222-4884 • info@bloodcancers.ca • bloodcancers.ca